Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Phase 2

Recruiting

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Drug: Osimertinib
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2020-06-01

Last Posted Date: 2025-06-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 571

Registration Number: NCT04410796

Locations: 🇺🇸
UC Davis Cancer Center (Data Collection Only), Sacramento, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 15 locations

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Phase 2

Active, not recruiting

Conditions: Primary Central Nervous System Lymphoma (PCNSL)

Interventions: Drug: Nivolumab

First Posted Date: 2020-05-26

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT04401774

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States

and more 4 locations

Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging

Not Applicable

Recruiting

Conditions: Esophageal Cancer

Interventions: Other: Injection of indocyanine green (ICG)dye
Device: Near-Infrared Image-Guided
Procedure: Sentinel Lymph Node (SLN) mapping

First Posted Date: 2020-05-22

Last Posted Date: 2025-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT04400292

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: Cyclical Hypofractionated Palliative Radiation (Quad Shot)
Behavioral: EORTC QLQ-C30 questionnaire

First Posted Date: 2020-05-12

Last Posted Date: 2025-06-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT04384146

Locations: 🇺🇸
Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

Phase 2

Terminated

Conditions: COVID-19
Cancer

Interventions: Other: Placebo
Drug: Hydroxychloroquine
Radiation: Radiation therapy

First Posted Date: 2020-05-11

Last Posted Date: 2021-10-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT04381988

Locations: 🇺🇸
Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States
🇺🇸
Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Phase 2

Withdrawn

Conditions: COVID-19
COVID19
Sars-CoV2
SARS-Cov-2

Interventions: Other: Placebo
Drug: Hydroxychloroquine

First Posted Date: 2020-05-07

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT04379492

Locations: 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Tocilizumab

First Posted Date: 2020-05-06

Last Posted Date: 2025-05-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT04377659

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of N-acetylcysteine in Patients With COVID-19 Infection

Phase 2

Active, not recruiting

Conditions: Covid-19

Interventions: Drug: N-acetylcysteine
Other: Peripheral Blood

First Posted Date: 2020-05-05

Last Posted Date: 2025-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT04374461

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

Phase 2

Active, not recruiting

Conditions: Leptomeningeal Metastases

Interventions: Radiation: Proton Craniospinal Irradiation (CSI)
Radiation: Involved-field Photon Radiation Therapy
Other: Neurocognitive Assessment
Other: MDASI-BT and MDASI-SP

First Posted Date: 2020-04-13

Last Posted Date: 2025-05-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 102

Registration Number: NCT04343573

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Phase 1

Completed

Conditions: Renal Cell Carcinoma
Unresectable Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: Talazoparib
Drug: Axitinib

First Posted Date: 2020-04-08

Last Posted Date: 2025-05-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT04337970

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy